Table 4 Univariate analyses for overall survival in metastatic gastric cancer patients who underwent surgery (n = 83)
From: Identification of prognostic factors and surgical indications for metastatic gastric cancer
Variable | Median survival (months) | p value |
|---|---|---|
Age (years) | 0.269 | |
>65 | 16.0 | |
< 65 | 15.6 | |
Sex | 0.211 | |
Male | 16.6 | |
Female | 11.1 | |
Body mass index (kg/m2) | 0.647 | |
>21 | 17.2 | |
< 21 | 14.2 | |
Hb (g/dL) | 0.423 | |
>12 | 17.2 | |
< 12 | 14.4 | |
NLR | < 0.001 | |
>3.1 | 21.9 | |
< 3.1 | 11.1 | |
CRP (mg/dL) | 0.016 | |
>0.2 | 11.1 | |
< 0.2 | 17.2 | |
Alb (g/dL) | 0.001 | |
>3.5 | 17.7 | |
< 3.5 | 9.8 | |
CEA (ng/mL) | 0.022 | |
≤ 6 | 16.8 | |
>6 | 13.4 | |
CA19-9 (U/mL) | 0.001 | |
≤ 37 | 17.7 | |
>37 | 10.1 | |
Tumor location in stomach | 0.426 | |
Upper | 16.2 | |
Middle | 15.6 | |
Lower | 16.0 | |
Whole | 13.1 | |
Adjacent organ invasion | 0.364 | |
Yes | 13.1 | |
No | 16.2 | |
Bulky lymph nodes | 0.149 | |
Yes | 13.4 | |
No | 17.7 | |
Histological differentiation | 0.404 | |
Differentiated | 16.0 | |
Undifferentiated | 15.6 | |
Metastasis to organs | 0.078 | |
1 organ | 17.7 | |
≥2 organs | 14.2 | |
Peritoneal metastasis | 0.213 | |
Yes | 12.5 | |
No | 17.7 | |
Hepatic metastasis | 0.784 | |
Yes | 16.5 | |
No | 14.4 | |
Distant lymph node metastasis | 0.973 | |
Yes | 14.9 | |
No | 16.5 | |
Surgical procedure | 0.017 | |
Gastrectomy | 12.5 | |
Gastrectomy + metastasectomy | 21.9 | |
Chemotherapy | 0.015 | |
Yes | 16.6 | |
No | 8.2 |